Sex-Related Differences in Conduit Strategy and Early Outcomes After Sternum-Sparing On-Pump Multivessel CABG via Left Anterior Thoracotomy - Top-Institutions - MDSpire

Sex-Related Differences in Conduit Strategy and Early Outcomes After Sternum-Sparing On-Pump Multivessel CABG via Left Anterior Thoracotomy

  • By

  • Demianenko, Volodymyr

  • Dörge, Hilmar

  • Grossmann, Marius

  • Belmenai, Ahmed

  • Sellin, Christian

  • April 27, 2026

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic Heart, Vascular & Thoracic Institute
    Cleveland Clinic Heart, Vascular & Thoracic Institute

    Cleveland, Ohio

    Key Differentiators

    • Cardiology
    • Heart Surgery

  • #2

    Mount Sinai Fuster Heart Hospital
    Mount Sinai Fuster Heart Hospital

    New York, New York

    Key Differentiators

    • Cardiology
    • Heart Surgery

  • #3

    German Heart Center Munich
    German Heart Center Munich

    Munich, Bavaria

    Key Differentiators

    • Cardiothoracic Surgery

  • #4

    University Hospital Schleswig–Holstein, Campus Kiel
    University Hospital Schleswig–Holstein, Campus Kiel

    Kiel, Schleswig-Holstein

    Key Differentiators

    • Cardiothoracic Surgery

  • #5

    Skane University Hospital
    Skane University Hospital

    Lund, Skåne

    Key Differentiators

    • Cardiothoracic Surgery

Original Source(s)

Sex-Related Differences in Conduit Strategy and Early Outcomes After Sternum-Sparing On-Pump Multivessel CABG via Left Anterior Thoracotomy

  • by Demianenko, Volodymyr , Dörge, Hilmar , Grossmann, Marius , Belmenai, Ahmed , Sellin, Christian

  • April 27, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.